An ongoing dialogue on HIV/AIDS, infectious diseases,
April 14th, 2010
Maraviroc Rarely Used for Treatment-Naive Patients
Over in Journal of Infectious Diseases, the MERIT study was recently published (with Chuck Hicks’ Journal Watch summary here), demonstrating that maraviroc is non-inferior to efavirenz — provided that the enhanced-sensitivity tropism test is used to select appropriate candidates.
(The MERIT study began in 2004-5. Don’t think I’ll ever forget that, since the investigator meeting overlapped with this memorable series. Notable event pictured.)
Despite these favorable results from the trial — and the FDA approval of the drug for treatment-naive patients — I agree with Chuck that mariviroc will get little use in this population, if only because the “preferred” alternatives (efavirenz, atazanavir/r, darunavir/r, raltegravir) are so incredibly good.
Our reader poll (right side of page) confirms how rarely the drug is prescribed as initial therapy. I suspect that some of the respondents who said they have given the drug to these patients did so within a clinical trial, which would make the response even lower.
Will maraviroc — or another CCR5 antagonist — ever have widespread use in HIV treatment?
Call me an optimist, but I envision that these drugs will be part of an aggressive eradication strategy, somehow based on the remarkable case of “cure” following bone marrow transplantation from a CCR5-negative donor.
Hey, I can dream can’t I? Red Sox fans certainly did in 2004.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- The End of the War on Biomedical Science? September 19, 2026The turmoil of the past 20 months has inflicted lasting damage on American science and public health. But history and recent events suggest that the attacks will subside.
- Cerebral Schistosomiasis September 19, 2026A rice farmer presented to the ED after a 1-minute episode of arm and leg shaking on the right side. MRI showed linear enhancement associated with a cluster of enhancing nodules and surrounding edema in the left frontal lobe.
- Human Adenovirus B3–Induced Immune Thrombocytopenia and Thrombosis September 17, 2026Virus-induced immune thrombocytopenia and thrombosis after HAdV-B3 infection supports a shared platelet factor 4–targeted immune mechanism linking natural adenovirus infection and adenoviral vector–associated disease.
- Honoring the Legacy of the HIV Epidemic September 17, 2026Progress against the U.S. HIV epidemic is stalling, owing in part to government attacks and fear. But clinicians, patients, and activists can learn from the epidemic’s early heroes and find ways to advance.
- Short or Long Antibiotic Regimens in Orthopedics September 16, 2026In a randomized trial involving adults who received local antibiotics during surgery for orthopedic infection, a short duration of systemic antibiotics was noninferior to a long duration regarding treatment failure at 12 months.
- The End of the War on Biomedical Science? September 19, 2026